ACCEL Lite: AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of CV Events in Patients with HTN

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research - Un podcast de American College of Cardiology - Les mardis

Catégories:

Thiazides are recommended first line agents for the treatment of hypertension.  They have been demonstrated to lower cardiovascular disease.  Which thiazide to choose has been a long-standing issue. In this interview, Areef Ishani MD, MS and W. Douglas Weaver MD, MACC discuss AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients with Hypertension. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Visit the podcast's native language site